Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;9(1):21-27.
doi: 10.5114/ceh.2023.125917. Epub 2023 Mar 17.

Investigation of liver fibrosis with serum biochemical parameters before treatment with direct-acting antivirals, at the end of treatment, and in the first and third year after treatment in patients with chronic hepatitis C

Mediha Bozkurt  1 , Esra Zerdali  2 , Filiz Pehlivanoğlu  2
Affiliations

Investigation of liver fibrosis with serum biochemical parameters before treatment with direct-acting antivirals, at the end of treatment, and in the first and third year after treatment in patients with chronic hepatitis C

Mediha Bozkurt et al. Clin Exp Hepatol. 2023 Mar.

Abstract

Aim of the study: In the treatment of chronic hepatitis C, the need for non-invasive methods, other than invasive methods, is increasing for the detection of fibrosis before and after treatment. In our study, we aimed to determine the changes in histological response with post-treatment biochemical scoring in patients treated with direct-acting antivirals.

Material and methods: Between June 1, 2016, and January 1, 2020, 125 patients followed up with a diagnosis of chronic hepatitis C, who presented to Haseki Training and Research Hospital, were enrolled in the study. Scores of APRI, Fibro Q, Fibrosis-4 (FIB-4) index, Doha score, Fibro alpha, and fibrosis-cirrhosis index were used to evaluate the liver fibrosis of the patients with examinations before treatment, at the end of treatment and at the 12th week, first year, and third year after treatment. The study was conducted as a retrospective observational case series.

Results: One hundred twenty-five patients were enrolled in the study. The mean age was 55.5 ±15.9 years. Patients were divided into two groups according to their baseline FIB-4 values: cirrhotic/noncirrhotic. Seven (5.6%) patients had compensated cirrhosis; there were no decompensated cirrhotic patients. There was a statistically significant decrease in scores of APRI, FIB-4, Fibro Q, and Doha score calculated during the end-of-treatment three-year follow-up period.

Conclusions: It was shown that serum fibrosis scores, such as APRI, FIB-4, Fibro Q, and Doha score, could be used to detect fibrosis before treatment and to follow histological improvement after treatment with direct-acting antivirals (DAA) in chronic hepatitis C patients.

Keywords: chronic hepatitis C; fibrosis; noninvasive tests.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
ROC analysis for the cut-off point of pretreatment scores predicting the presence of biopsy fibrosis
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. El-Kamary SS, Kottilil S. Viral hepatitis. In: Ryan ET. Hunter’s Tropical Medicine and Emerging Infectious Diseases, 10th edition. 2020; 35:308-324.
    1. Everhart JE, Wright EC, Goodman ZD, et al. . Prognostic value of ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010; 51: 585-594. - PMC - PubMed
    1. Holmberg SD, Lu M, Rupp LB, et al. . Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013; 57: 240-246. - PMC - PubMed
    1. World Health Organisation, News room, fact sheets, cancer. In: WHO [Internet]. 21 September 2021. http://www.who.int/news-room/fact-sheets/detail/cancer.
    1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021; 73: 4-13. - PMC - PubMed